Research Notes
Share to Facebook Share to Twitter Share to LinkedIn

Two Diabetes Drugs Outperform Others

Two Diabetes Drugs Outperform Others

In a large clinical trial comparing four drugs commonly used to treat type 2 diabetes (T2D), researchers from around the country, including at Einstein and Montefiore, found that insulin glargine U-100 and liraglutide performed the best of four drugs approved by the U.S. Food and Drug Administration to maintain blood glucose levels in the recommended range. 

Blood glucose management is crucial for keeping people with T2D healthy. All four evaluated drugs were added to treatment with metformin, the first-line drug for treating T2D. Their findings were published online on Sept. 21, 2022, in a pair of papers in the New England Journal of Medicine (NEJM). 

Jill Crandall, M.D., professor of medicine and the Jacob A. and Jeanne E. Barkey Chair in Medicine at Einstein, and chief of endocrinology at Einstein and Montefiore, was a coauthor on one of the NEJM papers.

Share to Facebook Share to Twitter Share to LinkedIn

More From Einstein

Einstein Students Celebrate Match Day
Supporting Underrepresented Students
The Virus Hunter: Jonathan Lai, Ph.D.
Graduate Students Win Marmur Award
Women in Science Day 2023
Einstein Celebrates Black History Month
Medical Student Gets Research Fellowship


Campus News
Research Notes
Motivations: Donors & Alumni

Past Issues

Download Magazine